- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.03. | NICE says no to Genmab cervical cancer therapy | ||
| 11.03. | Veeva buys brand engagement firm Ostro for $100m | ||
| 10.03. | FDA approves leucovorin - but not for autism | ||
| 10.03. | FDA cuts testing requirements for biosimilars once again | ||
| 10.03. | BioNTech bigwigs will step down to form new mRNA company | ||
| 10.03. | Lundbeck names AI head in quest to become 'bionic' company | ||
| 10.03. | BMS eyes another celmod filing in myeloma after phase 3 win | ||
| 09.03. | Novo partners with Hims & Hers again, ending GLP-1 spat | ||
| 09.03. | Incyte breaks new ground in anal cancer with EU approval | ||
| 09.03. | Alfasigma licenses liver drug from GSK in $590m deal | ||
| 09.03. | Roche's oral SERD flunks phase 3 breast cancer test | ||
| 09.03. | Safety concerns prompt Ipsen to pull Tazverik from market | ||
| 06.03. | Servier snaps up cancer biotech Day One in $2.5bn deal | ||
| 06.03. | Zealand Pharma hit as Roche-partnered obesity drug disappoints | ||
| 06.03. | Daiichi teams up with GAIA for cholesterol DTx in Europe | ||
| 06.03. | China's clears Pfizer GLP-1 ecnoglutide for weight loss | ||
| 06.03. | J&J's Tecvayli claims third national priority FDA approval | ||
| 06.03. | Alnylam bets on Tenaya RNAi tech, and other licensing news | ||
| 05.03. | Lilly unveils employer scheme for weight-loss drug Zepbound | ||
| 05.03. | PepGen slumps as FDA places hold on lead drug | ||
| 05.03. | Can GLP-1 drugs help tackle addiction? | ||
| 05.03. | Hansa closes on FDA verdict for transplant drug imlifidase | ||
| 05.03. | Welsh firm Antiverse raises funds for AI antibody platform | ||
| 04.03. | Five projects share £100m UK-US Cancer Grand Challenges fund | ||
| 04.03. | Moderna agrees $950m settlement of mRNA jab litigation |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.